Aura Biosciences is a biotechnology company developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed.

Register for Details

For more details on financing and valuation of private companies similar to Aura Biosciences before its , register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Aura Biosciences

To invest in Aura Biosciences pre-IPO

Can you invest in Aura Biosciences pre-IPO?

You may invest in Aura Biosciences as it is a public company listed on the NASDAQ with ticker AURA. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Aura Biosciences before it goes public?

You can no longer sell shares of Aura Biosciences on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Aura Biosciences shares?

Forge can no longer determine the value of Aura Biosciences shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Aura Biosciences a publicly traded company?

Aura Biosciences became a public company following its IPO on 10/29/2021 and is now traded on the NASDAQ under the ticker AURA.

To learn more about Aura Biosciences potential IPO

Will Aura Biosciences go IPO?

Aura Biosciences became a public company following its IPO on 10/29/2021 and is now traded on the NASDAQ under the ticker AURA.

What is Aura Biosciences’ IPO price?

The IPO price of Aura Biosciences is not currently available.

When was Aura Biosciences founded?

Aura Biosciences was founded in 2009.

What is Aura Biosciences funding to date?

Aura Biosciences has raised $225.08MM to date.

Aura Biosciences Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
03/22/2021 Series E $80.48MM $xx.xx $283.03MM Adage Capital Management Lp, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Lundbeckfonden Ventures, Matrix Capital Management, Medicxi, Rock Springs Capital, Surveyor Capital, Velosity Capital, Ysios Capital
Price per Share
$xx.xx
Shares Outstanding
102,671,041
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Adage Capital Management Lp, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Lundbeckfonden Ventures, Matrix Capital Management, Medicxi, Rock Springs Capital, Surveyor Capital, Velosity Capital, Ysios Capital
07/09/2020 Series D-2 $17MM $xx.xx $157.27MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
24,598,481
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Undisclosed Investors
04/02/2019 Series D-1 $40MM $xx.xx $139.53MM Advent Life Sciences, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Lundekfonden Ventures, Medicxi, Ysios Capital
Price per Share
$xx.xx
Shares Outstanding
57,878,742
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Lundekfonden Ventures, Medicxi, Ysios Capital
12/21/2017 Series C-2 $12.12MM $xx.xx $73.09MM Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital
Price per Share
$xx.xx
Shares Outstanding
33,218,192
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital
12/21/2017 Series C-1 $30.29MM $xx.xx $73.09MM Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital
Price per Share
$xx.xx
Shares Outstanding
58,109,711
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital
03/05/2015 Series B $28.21MM $xx.xx $50.26MM Advent Life Sciences, Alexandria Venture Investments, Chiesi Ventures, Li-Cor Biosciences, Ysios Capital
Price per Share
$xx.xx
Shares Outstanding
22,705,646
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Alexandria Venture Investments, Chiesi Ventures, Li-Cor Biosciences, Ysios Capital
08/17/2014 Series A-2 $5.37MM $xx.xx $22.08MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
4,325,021
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
07/04/2013 Series A-1 $8.2MM $xx.xx $29.11MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
3,298,732
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
08/26/2011 Series A $3.4MM $xx.xx $16MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
1,701,141
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
Updated on: Dec 4, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.